리시노프릴 시장 : 용량, 투여 강도, 환자 연령대, 용도, 유통 채널별 - 세계 예측

Lisinopril market size is anticipated to grow at 4.8% CAGR between 2024 and 2032 driven primarily by the increasing prevalence of cardiovascular diseases. As per WHO, cardiovascular diseases are the world's leading cause of death, claiming approximately 17.9 million lives annually. As these conditions become more common due to aging populations, sedentary lifestyles, and poor dietary habits, the demand for effective treatments like lisinopril, will soar.

The increasing focus on healthcare infrastructure and access to medical care in emerging economies will also influence market growth. Governments and healthcare organizations are investing heavily in improving healthcare services and making essential medications more accessible and affordable. The higher availability of generic versions of lisinopril, which are cost-effective alternatives to branded drugs, will further expand the product reach among the lower-income population.

The industry is segmented into dosage, dosage strength, patient age group, application, distribution channel, and region.

Based on dosage, the lisinopril market from the liquid segment will gain significant traction between 2024 and 2032 due to its increasing popularity among patients who have difficulty swallowing pills, such as the elderly and young children. Liquid formulations offer a convenient and easily adjustable dosage form while enhancing patient compliance and ensuring accurate dosing. The ease of administration and flexibility provided by liquid lisinopril will add to the segment growth.

The lisinopril market from the hypertension application segment is anticipated to witness significant growth from 2024 to 2032 owing to the growing prevalence of hypertension worldwide. Lisinopril is commonly prescribed to manage hypertension by relaxing blood vessels and reducing blood pressure. The increasing awareness of the health risks associated with unmanaged hypertension, along with improved screening and diagnostic practices, are stimulating the segment expansion.

Asia Pacific lisinopril industry is anticipated to grow at a notable pace over 2024-2032 attributed to the rapid economic development and improving healthcare infrastructure leading to easy access to medical treatments and pharmaceuticals. Increasing government initiatives to combat non-communicable diseases, coupled with expanding health insurance coverage are facilitating greater adoption of prescription medications, further boosting the regional product demand.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of hypertension and cardiovascular diseases
    • 3.2.1.2 Increasing aging population
    • 3.2.1.3 Growing awareness and screening programs
    • 3.2.1.4 Innovations in drug delivery
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Adverse effects and safety concerns
    • 3.2.2.2 Alternative treatment options
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Competitive positioning matrix
• 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Dosage, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Tablet
• 5.3 Liquid

Chapter 6 Market Estimates and Forecast, By Dosage Strength, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 10 Mg
• 6.3 20 Mg
• 6.4 25 Mg

Chapter 7 Market Estimates and Forecast, By Patient Age Group, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Children
• 7.3 Adults

Chapter 8 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hypertension
• 8.3 Heart failure
• 8.4 Heart attack
• 8.5 Diabetic kidney disease
• 8.6 Other applications

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacy
• 9.3 Retail pharmacy
• 9.4 Online pharmacy

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
  • 10.5.4 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 AbbVie Inc.
• 11.2 Amneal Pharmaceutical, Inc.
• 11.3 AstraZeneca
• 11.4 Apotex Inc.
• 11.5 Aurobindo Pharma Ltd.
• 11.6 Bausch Health Companies, Inc.
• 11.7 Cipla Limited
• 11.8 Hikma Pharmaceutical PLC.
• 11.9 Lupin Limited
• 11.10 Merck & Co., Inc.
• 11.11 Pfizer Inc.
• 11.12 Sun Pharmaceutical Industries Limited
• 11.13 Teva Pharmaceutical Industries Limited
• 11.14 Vitaris Inc.
• 11.15 Zydus Lifesciences Limited